The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 14 results:
[ Author(Desc)] Title Type Year
Filters: Author is Apostolidis, Apostolos  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Apostolidis, A., Kirana P-S., Chiu G., Link C., Tsiouprou M., & Hatzichristou D. (2009).  Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: results from the hospitalised and outpatients' profile and expectations study.. Eur Urol. 56(6), 937-47.
Apostolidis, A., Wagg A., A'i M. S. Rahnam, Panicker J. N., Vrijens D., & von Gontard A. (2018).  Is there "brain OAB" and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017.. Neurourol Urodyn. 37(S4), S38-S45.
Apostolidis, A. (2015).  Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?. Curr Drug Targets. 16(11), 1187-97.
Apostolidis, A. (2019).  Is there enough evidence to support sacral neuromodulation as a viable treatment option in children and adolescents with neurogenic lower urinary tract dysfunction?. World J Urol. 37(12), 2811-2812.
Apostolidis, A. (2017).  Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?. BJU Int. 120(4), 459-460.
Apostolidis, A. (2015).  Words of wisdom. Re: Intrathecal administration of botulinum toxin type a improves urinary bladder function and reduces pain in rats with cystitis.. Eur Urol. 67(4), 816.
Apostolidis, A., & Cameron A. P. (2020).  Neurourological Management After Failed Intradetrusor OnabotulinumtoxinA Injections.. Eur Urol Focus. 6(5), 814-816.
Apostolidis, A., Averbeck M. Augusto, Sahai A., Rahnama'i M. Sajjad, Anding R., Robinson D., et al. (2017).  Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015).. Neurourol Urodyn. 36(4), 882-893.
Apostolidis, A. (2013).  Male lower urinary tract symptoms: a riddle waiting to be solved.. Eur Urol. 64(3), 408-10.
Apostolidis, A., Papaefstathiou E., & Gatsos S. (2020).  Intravesical Botox for overactive bladder; how to minimize complications and manage failures.. Curr Drug Targets.
Apostolidis, A., Rantell A., Anding R., Kirschner-Hermanns R., & Cardozo L. (2017).  How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2.. Neurourol Urodyn. 36(4), 869-875.
Apostolidis, A., Thompson C., Yan X., & Mourad S. (2013).  An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.. World J Urol. 31(6), 1469-74.
Apostolidis, A., Papaefstathiou E., & Gatsos S. (2020).  Intravesical Botox for Overactive Bladder: How to Minimize Complications and Manage Failures. Current Drug Targets. 21(15), 1527 - 1536.
Apostolidis, A., Rahnama'i M. S., Fry C., Dmochowski R., & Sahai A. (2016).  Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.. Neurourol Urodyn. 35(2), 293-8.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.